Literature DB >> 12163388

Frequent Fas gene mutations in testicular germ cell tumors.

Hitoshi Takayama1, Tetsuya Takakuwa, Yuichi Tsujimoto, Yoichi Tani, Norio Nonomura, Akihiko Okuyama, Shigekazu Nagata, Katsuyuki Aozasa.   

Abstract

The Fas (Apo-1/CD95)/Fas ligand (L) system is involved in cell death signaling, and has been suggested to be important for the regulation of germ cell apoptosis in the testis. Mutations of the Fas gene may result in accumulation of germ cells and thus might contribute to testicular carcinogenesis. The open reading frame of Fas cDNA was examined in 24 cases of testicular germ cell tumors (TGCTs), comprised of 19 pure histological type (15 seminomas, 3 embryonal carcinomas, 1 immature teratoma) and 5 mixed-type tumors. Mutations of the Fas gene were found in nine (37.5%) of these cases. Each lesion with a homogeneous histological picture was selectively microdissected using a laser capture microdissection method: samples consisted of 18 lesions from seminomas, 7 embryonal carcinomas, 4 immature teratomas, 2 choriocarcinomas, and 1 from a yolk sac tumor. Microdissected genomic DNA was examined to determine which mutations were derived from which kind of histological lesion. Eleven mutations were detected in 10 TGCT lesions from nine cases, but none were found in benign lesions. All were point mutations, and eight missense mutations occurred in exon 9 encoding the core protein of the death domain essential for apoptotic signal transduction. Three were silent mutations. Mutations were found in the seminoma (27.8%) and embryonal carcinoma lesions (62.5%), but none were found in the one yolk sac tumor, two choriocarcinomas, or four immature teratoma lesions. Each seminoma and embryonal carcinoma lesion found in the same case had a different type of Fas mutation from the others. Mouse T-cell lymphoma cells transfected with missense mutated genes were resistant to apoptosis induced by anti-Fas antibody, indicating these to be loss-of-function mutations. These findings suggested a role of Fas gene mutations in the pathogenesis of TGCTs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163388      PMCID: PMC1850755          DOI: 10.1016/S0002-9440(10)64219-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  pEF-BOS, a powerful mammalian expression vector.

Authors:  S Mizushima; S Nagata
Journal:  Nucleic Acids Res       Date:  1990-09-11       Impact factor: 16.971

2.  Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity.

Authors:  K Grønbaek; P T Straten; E Ralfkiaer; V Ahrenkiel; M K Andersen; N E Hansen; J Zeuthen; K Hou-Jensen; P Guldberg
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

3.  Fas gene mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens.

Authors:  H Takayama; T Takakuwa; Z Dong; N Nonomura; A Okuyama; S Nagata; K Aozasa
Journal:  Lab Invest       Date:  2001-03       Impact factor: 5.662

4.  Frequent mutations of Fas gene in thyroid lymphoma.

Authors:  T Takakuwa; Z Dong; H Takayama; F Matsuzuka; S Nagata; K Aozasa
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

5.  The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis.

Authors:  S E Straus; E S Jaffe; J M Puck; J K Dale; K B Elkon; A Rösen-Wolff; A M Peters; M C Sneller; C W Hallahan; J Wang; R E Fischer; C E Jackson; A Y Lin; C Bäumler; E Siegert; A Marx; A K Vaishnaw; T Grodzicky; T A Fleisher; M J Lenardo
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

6.  Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder.

Authors:  S H Lee; M S Shin; W S Park; S Y Kim; S M Dong; J H Pi; H K Lee; H S Kim; J J Jang; C S Kim; S H Kim; J Y Lee; N J Yoo
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

Review 7.  Pathology of germ cell tumors of testis: a progress report.

Authors:  F K Mostofi
Journal:  Cancer       Date:  1980-04-15       Impact factor: 6.860

8.  Comparison of various clinical and pathological classifications of tumors of testes.

Authors:  F K Mostofi
Journal:  Semin Oncol       Date:  1979-03       Impact factor: 4.929

9.  Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene.

Authors:  Q R Huang; D Morris; N Manolios
Journal:  Mol Immunol       Date:  1997-06       Impact factor: 4.407

10.  Germ cell tumours of testis: prognostic factors and results.

Authors:  D Nikzas; A E Champion; M Fox
Journal:  Eur Urol       Date:  1990       Impact factor: 20.096

View more
  2 in total

Review 1.  CD95-mediated cell signaling in cancer: mutations and post-translational modulations.

Authors:  Sébastien Tauzin; Laure Debure; Jean-François Moreau; Patrick Legembre
Journal:  Cell Mol Life Sci       Date:  2011-11-01       Impact factor: 9.261

Review 2.  New insights into the pathology and molecular biology of human germ cell tumors.

Authors:  Friedemann Honecker; J Wolter Oosterhuis; Frank Mayer; Jörg Thomas Hartmann; Carsten Bokemeyer; Leendert H J Looijenga
Journal:  World J Urol       Date:  2004-03-20       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.